Sentence examples for moderate immunoreactivity over from inspiring English sources

Both HCS and TSB were immunoreactive for type I collagen, however, HCS had mild, patchy intracellular immunoreactivity while TSB had diffuse moderate immunoreactivity over the entire bisocaffold.

TSB 8 of 9 dogs had moderate to strong type I intracellular immunoreactivity over 50% of the cell population, with diffuse moderate immunoreactivity over the entire bioscaffold.

After pre-enrichment with the tissue of turbot for 6 h, a moderate immunoreactivity was observed in the turbot homogenate samples inoculated with E. tarda over 103 CFU/ml (Figure 5A).

In addition, the cytoplasm of lymphocytes demonstrated weak to moderate immunoreactivity as noted in tumors bearing many of these cells such as some germinoma.

The immunohistochemical signal intensities were also classified into four groups: 0, no immunoreactivity; 1, weak immunoreactivity; 2, moderate immunoreactivity; 3, strong immunoreactivity.

The staining intensity was graded on a scale of 0 to 3+ (0 for no staining, 1+ for weak immunoreactivity; 2+ for moderate immunoreactivity; and 3+ for strong immunoreactivity).

Grade 1 corresponded to weak immunoreactivity present in about 50% of neurons; grade 2 corresponded to moderate immunoreactivity in almost all neurons; and grade 3 corresponded to strong immunoreactivity present in almost all neurons in a given brain structure.

In contrast, strong immunoreactivity to CML (figure 1E), moderate immunoreactivity to pyrraline (figure 1F) and weak immunoreactivity to pentosidine (figure 1G) were seen in the superficial layers of the corneal stroma.

The overall intensity of the staining reaction was scored with 0 indicating no immunoreactivity and no positive cells, 1+ weak immunoreactivity and < 10% of positive cells, 2+ mild immunoreactivity and 10 30% of positive cells, 3+ moderate immunoreactivity and 31 60% of positive cells, and 4+ strong immunoreactivity and 61 100% of positive cells.

In BPH, both basal and luminal epithelial (Ep) cells generally exhibited low to moderate immunoreactivity for SPRY2 expression (Supporting Information Fig S1).

In contrast, only moderate immunoreactivity for these markers were detected in 44.3% and 17.8% of normal tissues, respectively.